This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Thank you to everyone in the CCA community who contributed to the public consultation into use of Faecal Calprotectin (FC) tests.
The Gastroenterological Society of Australia (GESA) Led Application for faecal calprotectin for the monitoring of disease activity in patients with inflammatory bowel disease was approved by Medical Services Advisory Committee (MSAC) on 6 February 2025.
The recommendation will need to be approved by the Minister for Health and Aged Care before listing on the MBS which is anticipated to be later this year.